Which patients are contraindicated for muscle relaxant therapy?

Who Cannot Take Muscle Relaxants

Suxamethonium (succinylcholine) is absolutely contraindicated in patients with primary muscle damage (myopathies, muscular dystrophies) and in those with up-regulation of nicotinic acetylcholine receptors (chronic motor deficits, extensive burns, prolonged critical illness) due to life-threatening risks of rhabdomyolysis and hyperkalemia. 1

Absolute Contraindications to Suxamethonium

Primary Muscle Damage

• Myopathies (including Duchenne muscular dystrophy)
• Myotonic disorders
• Suxamethonium induces generalized muscle contraction leading to rhabdomyolysis in these conditions 1

Up-regulation of Nicotinic Acetylcholine Receptors

• Chronic motor deficits (e.g., spinal cord injury, stroke with paralysis)
• Extensive or deep burns (beginning 24 hours post-injury)
• Prolonged critical illness
• Denervation syndromes (e.g., amyotrophic lateral sclerosis)

The risk period for hyperkalemia begins 24 hours after the inciting event and persists for at least 6 months, though the exact duration remains unknown 2. During this window, suxamethonium can trigger life-threatening hyperkalemia 1, 2.

Special Populations Requiring Extreme Caution

Neuromuscular Junction Disorders (Myasthenia Gravis)

• Non-depolarizing muscle relaxants are not contraindicated but require 50-75% dose reduction 1
• Patients show markedly increased sensitivity and prolonged duration of action
• Mandatory neuromuscular blockade monitoring to avoid overdosing 1
• If TOF ratio <0.9 before administration, sensitivity is even greater and doses must be further reduced 1

Severe Renal Failure (Creatinine Clearance <30 mL/min)

• Rocuronium clearance is significantly reduced 1
• Preferred agents: Atracurium or cisatracurium (organ-independent elimination) 1
• Sugammadex efficacy is decreased in severe renal failure 1
• Initial dosing remains unchanged, but subsequent doses require careful titration 1

Hepatic Failure

• Rocuronium shows wide variability in duration with repeated dosing in cirrhotic patients 1
• Preferred agents: Atracurium or cisatracurium 1
• Initial dose unchanged, but monitor closely for prolonged effects 1

Elderly Patients

• Sugammadex efficacy is decreased 1
• Increased sensitivity to non-depolarizing agents
• Rocuronium duration of action is extended, though onset time remains normal 1

Critical Pitfalls to Avoid

1. Never use suxamethonium in myotonic disease - risk of triggering severe, prolonged muscle spasms 2

2. Avoid reversal agents (neostigmine) in primary muscle damage - causes problematic secretion drying, cardiac rhythm disturbances, and affects muscle action potentials 1

3. Do not assume muscle relaxants are safe in "stable" neuromuscular disease - pharmacodynamics are significantly altered even in compensated patients 1

4. The 24-hour rule for burns/denervation is critical - suxamethonium is safe immediately after injury but becomes dangerous within 24 hours 2

Monitoring Requirements

For all patients with neuromuscular disease receiving any muscle relaxant:

• Mandatory train-of-four (TOF) monitoring before, during, and after administration 1
• Pre-administration TOF ratio predicts sensitivity and guides dosing 1
• Sugammadex is the preferred reversal agent over neostigmine in these populations 1